CN107531703B - 用于治疗炎症性疾病的二氢吡啶并异喹啉酮类及其药物组合物 - Google Patents

用于治疗炎症性疾病的二氢吡啶并异喹啉酮类及其药物组合物 Download PDF

Info

Publication number
CN107531703B
CN107531703B CN201680023369.1A CN201680023369A CN107531703B CN 107531703 B CN107531703 B CN 107531703B CN 201680023369 A CN201680023369 A CN 201680023369A CN 107531703 B CN107531703 B CN 107531703B
Authority
CN
China
Prior art keywords
compound
independently selected
pharmaceutically acceptable
methyl
dihydrobenzo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201680023369.1A
Other languages
English (en)
Chinese (zh)
Other versions
CN107531703A (zh
Inventor
C·J·M·梅内特
J·G·P-O·多扬
P·I·R·克拉斯
B·阿拉尔
M·M·P·德瓦克泰
G·A·特里卡里特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Galapagos NV
Original Assignee
Galapagos NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galapagos NV filed Critical Galapagos NV
Publication of CN107531703A publication Critical patent/CN107531703A/zh
Application granted granted Critical
Publication of CN107531703B publication Critical patent/CN107531703B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201680023369.1A 2015-04-23 2016-04-19 用于治疗炎症性疾病的二氢吡啶并异喹啉酮类及其药物组合物 Active CN107531703B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1506894.3 2015-04-23
GBGB1506894.3A GB201506894D0 (en) 2015-04-23 2015-04-23 Novel dihydropyridoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory disorders
PCT/EP2016/058607 WO2016169911A1 (en) 2015-04-23 2016-04-19 Novel dihydropyridoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory disorders

Publications (2)

Publication Number Publication Date
CN107531703A CN107531703A (zh) 2018-01-02
CN107531703B true CN107531703B (zh) 2020-09-01

Family

ID=53488521

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680023369.1A Active CN107531703B (zh) 2015-04-23 2016-04-19 用于治疗炎症性疾病的二氢吡啶并异喹啉酮类及其药物组合物

Country Status (19)

Country Link
US (1) US10568879B2 (https=)
EP (1) EP3286191B1 (https=)
JP (1) JP6777652B2 (https=)
KR (1) KR20170139142A (https=)
CN (1) CN107531703B (https=)
AR (1) AR104362A1 (https=)
AU (1) AU2016251517A1 (https=)
BR (1) BR112017022008A2 (https=)
CA (1) CA2983342A1 (https=)
CO (1) CO2017011093A2 (https=)
GB (1) GB201506894D0 (https=)
IL (1) IL255109A0 (https=)
MX (1) MX2017013382A (https=)
PH (1) PH12017501911A1 (https=)
RU (1) RU2017134551A (https=)
SG (1) SG11201708671RA (https=)
TW (1) TW201702243A (https=)
WO (1) WO2016169911A1 (https=)
ZA (1) ZA201706674B (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3403649A1 (en) * 2017-05-16 2018-11-21 Bayer Pharma Aktiengesellschaft Inhibitors and antagonists of gpr84 for the treatment of endometriosis
CN106977483A (zh) * 2017-06-02 2017-07-25 遵义医学院 一种二氟烷基取代的黄酮醇、异黄酮醇和香豆素类化合物的合成方法
CN118239937A (zh) 2017-08-09 2024-06-25 戴纳立制药公司 化合物、组合物及方法
DK3676297T3 (da) 2017-09-01 2023-08-14 Denali Therapeutics Inc Forbindelser, sammensætninger og fremgangsmåder
RU2020119415A (ru) * 2017-11-15 2021-12-16 Галапагос Нв Соединения и их фармацевтические композиции для применения при лечении фиброзных заболеваний
WO2020007342A1 (zh) * 2018-07-06 2020-01-09 中国科学院上海药物研究所 联苯磷酸酯类化合物作为gpr84拮抗剂的应用
MA54953A (fr) * 2019-02-13 2021-12-22 Denali Therapeutics Inc Composés, compositions et procédés
US12091392B2 (en) 2019-02-13 2024-09-17 Denali Therapeutics Inc. Compounds, compositions and methods
BR112022011237A2 (pt) 2019-12-19 2022-08-30 Bayer Ag Derivados de furoindazol
WO2021123394A1 (en) 2019-12-20 2021-06-24 University Of Copenhagen G protein-coupled receptor modulators and a pharmaceutical composition
US12378229B2 (en) 2021-02-02 2025-08-05 Liminal Biosciences Limited GPR84 antagonists and uses thereof
WO2022179940A1 (en) 2021-02-23 2022-09-01 Bayer Aktiengesellschaft Furoindazole derivatives as gpr84 antagonists
WO2022218372A1 (zh) * 2021-04-14 2022-10-20 武汉人福创新药物研发中心有限公司 一种二氢嘧啶并异喹啉酮类衍生物及用途
EP4330260A1 (en) 2021-04-29 2024-03-06 Bayer Aktiengesellschaft Furoindazole derivatives as antagonists or inhibitors of gpr84
EP4355743A1 (en) 2021-06-18 2024-04-24 University of Copenhagen Polysubstituted 4-hydroxypyridine and 4-hydroxyquinoline derivatives as gpr84 antagonists
CN115611944A (zh) 2021-07-15 2023-01-17 中国科学院上海药物研究所 不对称gpr84拮抗剂及其用途
WO2024083705A1 (en) 2022-10-18 2024-04-25 Bayer Aktiengesellschaft Furoindazole derivatives for the treatment of pain
USD1117011S1 (en) * 2024-07-10 2026-03-10 Delta Electronics, Inc. Charging connector
USD1119767S1 (en) * 2024-07-10 2026-03-24 Delta Electronics, Inc. Charging connector

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1284954A (zh) * 1997-12-23 2001-02-21 应用研究系统Ars股份公司 苯并[c]喹嗪衍生物及其作为5α－还原酶抑制剂的用途
WO2005050225A2 (en) * 2003-10-31 2005-06-02 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 84 (gpr84)
CN103998448A (zh) * 2011-12-22 2014-08-20 加拉帕戈斯股份有限公司 用于治疗炎性疾病的新的二氢嘧啶并异喹啉酮化合物及其药用组合物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1929310A2 (en) 2005-09-02 2008-06-11 Arena Pharmaceuticals, Inc. Human g protein-coupled receptor and modulators thereof for the treatment of atherosclerosis and atherosclerotic disease and for the treatment of conditions related to mcp-1 expression
WO2012037782A1 (en) 2010-09-20 2012-03-29 Glaxo Group Limited Tricyclic compounds, preparation methods, and their uses
WO2014095798A1 (en) 2012-12-20 2014-06-26 Galapagos Nv Novel dihydropyrimidinoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory disorders (gpr84 antagonists)
GB201411241D0 (en) * 2014-06-25 2014-08-06 Galapagos Nv Novel dihydropyridoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory disorders

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1284954A (zh) * 1997-12-23 2001-02-21 应用研究系统Ars股份公司 苯并[c]喹嗪衍生物及其作为5α－还原酶抑制剂的用途
WO2005050225A2 (en) * 2003-10-31 2005-06-02 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 84 (gpr84)
CN103998448A (zh) * 2011-12-22 2014-08-20 加拉帕戈斯股份有限公司 用于治疗炎性疾病的新的二氢嘧啶并异喹啉酮化合物及其药用组合物

Also Published As

Publication number Publication date
SG11201708671RA (en) 2017-11-29
PH12017501911A1 (en) 2018-03-05
JP6777652B2 (ja) 2020-10-28
IL255109A0 (en) 2017-12-31
WO2016169911A1 (en) 2016-10-27
CA2983342A1 (en) 2016-10-27
MX2017013382A (es) 2017-12-07
GB201506894D0 (en) 2015-06-10
AU2016251517A1 (en) 2017-10-26
KR20170139142A (ko) 2017-12-18
US10568879B2 (en) 2020-02-25
JP2018513180A (ja) 2018-05-24
US20190062325A1 (en) 2019-02-28
BR112017022008A2 (pt) 2018-07-03
CO2017011093A2 (es) 2018-01-31
TW201702243A (zh) 2017-01-16
EP3286191A1 (en) 2018-02-28
AR104362A1 (es) 2017-07-12
ZA201706674B (en) 2019-07-31
EP3286191B1 (en) 2020-07-29
CN107531703A (zh) 2018-01-02
RU2017134551A (ru) 2019-04-04

Similar Documents

Publication Publication Date Title
CN107531703B (zh) 用于治疗炎症性疾病的二氢吡啶并异喹啉酮类及其药物组合物
JP6062453B2 (ja) 炎症性障害の治療のための新規ジヒドロピリミジノイソキノリノン及びその医薬組成物
EP3692040B1 (en) Chemical compounds
ES2905755T3 (es) Derivados de piperidina
CN104870445B (zh) 用于治疗炎性疾病的新二氢嘧啶并异喹啉酮类及其药物组合物(gpr84拮抗剂)
KR102517352B1 (ko) Nik 억제제로서의 헤테로방향족 유도체
WO2015197550A1 (en) Novel dihydropyridoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory disorders
JP2021527106A (ja) 新規化合物及び疾患の治療のためのその医薬組成物
JP2014507414A (ja) 代謝疾患及び炎症疾患の治療に有用なアゼチジン誘導体
JP6472454B2 (ja) 炎症性疾患治療のためのベンゾイミダゾール誘導体及びその医薬組成物
JP2016505021A (ja) Ｐｉｍキナーゼ阻害剤として有用な二環式芳香族カルボキサミド化合物
CN107106547A (zh) 作为Janus激酶抑制剂的乙基N‑Boc哌啶基吡唑并吡啶酮
CN110831940B (zh) 作为nik抑制剂的新取代的氮杂吲哚啉衍生物
TW201416348A (zh) 以氟甲基取代之吡咯甲醯胺
CN120584106A (zh) Nlrp3炎性小体抑制剂
CN111683945B (zh) Cxcr7受体拮抗剂的结晶型
CN112262129A (zh) 基于三氮杂环十二烷磺酰胺(“tcd”)的蛋白质分泌抑制剂
RU2780577C2 (ru) Новые замещенные производные азаиндолина в качестве ингибиторов nik
BR112019001551B1 (pt) Moduladores do receptor de piperidina cxcr7, seu uso e composição farmacêutica os compreendendo

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant